Non-Hodgkin lymphoma statistics

Coronavirus (COVID-19)

We have created a central resources hub for Health Professionals which hosts all of our CRUK resources and further materials to help with managing the pandemic. We are updating the information as guidance changes. There is also a page specifically for patients on our about cancer hub.

Health Professional COVID-19 and Cancer Hub

Cases

New cases of non-Hodgkin lymphoma, 2015-2017, UK

Deaths

Deaths from non-Hodgkin lymphoma, 2015-2017, UK

 

Survival

Survive non-Hodgkin lymphoma for 10 or more years, 2013-2017, England and Wales

Preventable cases

Non-Hodgkin lymphoma cases are preventable, UK, 2015

 

  • There are around 14,100 new non-Hodgkin lymphoma cases in the UK every year, that's 39 every day (2015-2017).
  • Non-Hodgkin lymphoma is the 6th most common cancer in the UK, accounting for 4% of all new cancer cases (2017).
  • In females in the UK, non-Hodgkin lymphoma is the 7th most common cancer, with around 6,300 new cases in 2017.
  • In males in the UK, non-Hodgkin lymphoma is the 7th most common cancer, with around 7,800 new cases in 2017.
  • Incidence rates for non-Hodgkin lymphoma in the UK are highest in people aged 80 to 84 (2015-2017).
  • Each year more than a third (36%) of all new non-Hodgkin lymphoma cases in the UK are diagnosed in people aged 75 and over (2015-2017).
  • Since the early 1990s, non-Hodgkin lymphoma incidence rates have increased by almost two-fifths (39%) in the UK. Rates in females have increased by almost two-fifths (39%) and rates in males have increased by more than a third (36%) (2015-2017).
  • Over the last decade, non-Hodgkin lymphoma incidence rates have increased by around a seventh (13%) in the UK. Rates in females have increased by around a tenth (11%), and rates in males have increased by around a seventh (13%) (2015-2017).
  • Most non-Hodgkin lymphoma cases are diagnosed at a late stage.
  • Incidence rates for non-Hodgkin lymphoma are projected to fall by 2% in the UK between 2014 and 2035, to 26 cases per 100,000 people by 2035.
  • Non-Hodgkin lymphoma in England is more common in females living in the most deprived areas. There is no association for males.
  • NHL is as common in White, Asian and Black people.
  • An estimated 76,800 people who had previously been diagnosed with non-Hodgkin lymphoma were alive in the UK at the end of 2010.

See more in-depth NHL incidence statistics

  • There are around 4,900 non-Hodgkin lymphoma deaths in the UK every year, that's 13 every day (2015-2017).
  • Non-Hodgkin lymphoma is the 11th most common cause of cancer death in the UK, accounting for 3% of all cancer deaths (2017).
  • In females in the UK, non-Hodgkin lymphoma is the 10th most common cause of cancer death, with around 2,200 deaths in 2017.
  • In males in the UK, non-Hodgkin lymphoma is the 14th most common cause of cancer death, with around 2,700 deaths in 2017.
  • Mortality rates for non-Hodgkin lymphoma in the UK are highest in people aged 85 to 89 (2015-2017).
  • Since the early 1970s, non-Hodgkin lymphoma mortality rates have increased by four-fifths (80%) in the UK. Rates in females have increased by almost three-quarters (73%), and rates in males have increased by more than four-fifths (84%).
  • Over the last decade, non-Hodgkin lymphoma mortality rates have decreased by more than a twentieth (7%) in the UK. Rates in females have decreased by around a tenth (9%), and rates in rates in males have decreased by around a twentieth (6%).
  • Mortality rates for non-Hodgkin lymphoma are projected to fall by 20% in the UK between 2014 and 2035, to 8 deaths per 100,000 people by 2035.
  • Non-Hodgkin lymphoma deaths in England are more common in females living in the most deprived areas. There is no association for males.

See more in-depth NHL mortality statistics

  • Around 8 in 10 (79.4%) of people diagnosed with non-Hodgkin lymphoma in England survive their disease for one year or more (2013-2017).
  • 2 in 3 (65.6%) of people diagnosed with non-Hodgkin lymphoma in England survive their disease for five years or more (2013-2017).
  • It is predicted that almost 6 in 10 (54.7%) of people diagnosed with non-Hodgkin lymphoma in England survive their disease for ten years or more (2013-2017).
  • Non-Hodgkin lymphoma survival for females is higher than for males at one-, five- and ten-years.
  • Non-Hodgkin lymphoma survival in England is highest for people diagnosed aged under 40 (2009-2013).
  • Almost 9 in 10 people in England diagnosed with Non-Hodgkin lymphoma aged 15-39 survive their disease for five years or more, compared with more than 4 in 10 people diagnosed aged 80 and over (2009-2013).
  • Non-Hodgkin lymphoma survival is improving and has tripled in the last 40 years in the UK.
  • In the 1970s, more than a fifth of people diagnosed with Non-Hodgkin lymphoma cancer survived their disease beyond ten years, now it's almost two-thirds.
  • Five-year relative survival for non-Hodgkin lymphoma in men is below the European average in England and Wales but similar to the European average in Scotland and Northern Ireland.
  • Five-year relative survival for non-Hodgkin lymphoma in women is below the European average in England but similar to the European average in Wales, Scotland and Northern Ireland.
  • A person’s risk of developing cancer depends on many factors, including age, genetics, and exposure to risk factors (including some potentially avoidable lifestyle factors).
  • 1 in 39 UK males and 1 in 51 UK females will be diagnosed with non-Hodgkin lymphoma in their lifetime.
  • 3% of non-Hodgkin lymphoma cases in the UK are preventable.

See more in-depth NHL risk statistics

  • 'GP referral' is the most common route to diagnosing non-Hodgkin lymphoma (NHL).
  • 'Two week wait' is the route with the highest proportion of cases diagnosed at an early stage, for NHL.
  • ‘Two-week wait’ and ’31-day wait’ standards are met by all countries, and ‘62-day wait’ is not met by any country for haematological cancers.

See more in-depth NHL diagnosis and treatment statistics

Want the key stats in the sections on this page as a document? or looking for a stats report of the in-depth stats? Use the print function at the bottom of any Cancer Stats page Share this page > Print or your browser options to print or save.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

We’re now on twitter.
Join the conversation and follow @CRUKHCPs for news, updates and opinion.

@CRUKHCPs

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.